Orthopediatrics Corp (KIDS) — SEC Filings
Orthopediatrics Corp (KIDS) — 46 SEC filings. Latest: 8-K (Apr 1, 2026). Includes 29 8-K, 6 10-Q, 4 SC 13G/A.
View Orthopediatrics Corp on SEC EDGAR
Overview
Orthopediatrics Corp (KIDS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Oct 29, 2025: OrthoPediatrics Corp. (KIDS) reported a net loss of $11.773 million for the three months ended September 30, 2025, a significant increase from the $7.919 million net loss in the prior-year quarter. For the nine months ended September 30, 2025, the net loss widened to $29.545 million, compared to $21
Sentiment Summary
Across 46 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 42 neutral, 1 mixed. The dominant filing sentiment for Orthopediatrics Corp is neutral.
Filing Type Overview
Orthopediatrics Corp (KIDS) has filed 29 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 4 SC 13G/A, 3 SC 13G with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (46)
Risk Profile
Risk Assessment: Of KIDS's 34 recent filings, 2 were flagged as high-risk, 6 as medium-risk, and 26 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $174.743M |
| Net Income | -$29.545M |
| EPS | N/A |
| Debt-to-Equity | 0.41 |
| Cash Position | $16.826M |
| Operating Margin | -17.8% |
| Total Assets | $493.486M |
| Total Debt | $110.945M |
Key Executives
- Dr. Richard L. Miller
- Dr. Steven L. Johnson
Industry Context
OrthoPediatrics Corp. operates in the pediatric orthopedic device market, a specialized segment of the broader orthopedic industry. This niche focuses on developing and marketing implants and instruments for the treatment of congenital, developmental, and trauma-related orthopedic conditions in children. The market is characterized by a need for specialized product designs and regulatory compliance tailored to pediatric patients.
Top Tags
financial-reporting (9) · 8-K (8) · material-agreement (5) · Medical Devices (4) · 8-k (4) · financials (4) · 10-Q (4) · corporate-governance (3) · sec-filing (3) · medical-devices (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $11.773M | Increased from $7.919M in Q3 2024, indicating widening losses. |
| Net Loss (9M 2025) | $29.545M | Widened from $21.753M in 9M 2024, showing persistent unprofitability. |
| Net Revenue (Q3 2025) | $61.250M | Increased from $54.573M in Q3 2024, demonstrating top-line growth. |
| Net Revenue (9M 2025) | $174.743M | Increased from $152.060M in 9M 2024, showing consistent revenue expansion. |
| Accumulated Deficit | $265.109M | Increased from $235.564M at Dec 31, 2024, highlighting ongoing losses. |
| Cash (Sep 30, 2025) | $16.826M | Decreased significantly from $43.820M at Dec 31, 2024, indicating substantial cash burn. |
| Long-term Term Loan | $48.065M | Increased from $23.957M at Dec 31, 2024, reflecting increased debt financing. |
| Intangible Asset Impairment (Q3 2025) | $2.268M | New expense contributing to increased operating losses. |
| Restructuring Costs (Q3 2025) | $2.294M | New expense contributing to increased operating losses. |
| Net Cash Used in Operating Activities (9M 2025) | $15.199M | Reduced from $23.061M in 9M 2024, but still a significant outflow. |
| Net Loss for Q2 2025 | $10.1M | Increased from $7.8 million in Q2 2024 |
| Net Loss for Six Months Ended June 30, 2025 | $20.5M | Increased from $15.5 million for the same period in 2024 |
| Accumulated Deficit as of June 30, 2025 | $20.5M | Increased from $15.5 million as of December 31, 2024 |
| Common Stock Shares Outstanding | 40,000 | Stable as of June 30, 2025 |
| Additional Paid-In Capital as of June 30, 2025 | $100.0M | Increased from $99.9 million as of December 31, 2024 |
Forward-Looking Statements
- {"claim":"OrthoPediatrics Corp. stock price may experience short-term volatility due to the institutional selling.","entity":"OrthoPediatrics Corp.","targetDate":"Q1 2024","confidence":"medium"}
Frequently Asked Questions
What are the latest SEC filings for Orthopediatrics Corp (KIDS)?
Orthopediatrics Corp has 46 recent SEC filings from Jan 2024 to Apr 2026, including 29 8-K, 6 10-Q, 4 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of KIDS filings?
Across 46 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 42 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Orthopediatrics Corp SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Orthopediatrics Corp (KIDS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Orthopediatrics Corp?
Key financial highlights from Orthopediatrics Corp's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for KIDS?
The investment thesis for KIDS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Orthopediatrics Corp?
Key executives identified across Orthopediatrics Corp's filings include Dr. Richard L. Miller, Dr. Steven L. Johnson.
What are the main risk factors for Orthopediatrics Corp stock?
Of KIDS's 34 assessed filings, 2 were flagged high-risk, 6 medium-risk, and 26 low-risk.
What are recent predictions and forward guidance from Orthopediatrics Corp?
Recent forward-looking statements from Orthopediatrics Corp include guidance on {"claim":"OrthoPediatrics Corp. stock price may experience short-term volatility due to the institutional selling.","ent.